Synopsis
Synopsis
0
USDMF
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Clopidogrel
2. Clopidogrel Besilate
3. Clopidogrel Besylate
4. Clopidogrel Bisulfate
5. Clopidogrel Mepha
6. Clopidogrel Napadisilate
7. Clopidogrel Sandoz
8. Clopidogrel, (+)(s)-isomer
9. Clopidogrel-mepha
10. Iscover
11. Pcr 4099
12. Pcr-4099
13. Plavix
14. Sc 25989c
15. Sc 25990c
16. Sr 25989
1. 120202-65-5
2. 426o7xws6y
3. Clopidogrel (tn)
4. Unii-426o7xws6y
5. Clopidogrel Hcl
6. Clopidogrel-hcs
7. Clopidogrel-tad
8. Clopidogrel-dura
9. Clopidogrel-hydrochlorid
10. Clopidogrel-krka
11. Clopidogrel Mylan
12. Clopidogrel Qualimed
13. Clopidogrel Teva Pharma
14. Schembl1031047
15. Dtxsid40152734
16. Clopidogrel Teva Generics B.v.
17. Clopidogrel Hydrochloride [who-dd]
18. Clopidogrel Hydrochloride [ema Epar]
19. Cs-0165212
20. Clopidogrel Hydrochloride [ep Monograph]
21. D10823
22. Q27258500
23. (s)-methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate Hydrochloride? (clopidogrel Impurity Pound(c)
24. Methyl (2s)-2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate;hydrochloride
25. Methyl-(s)-(+)-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridine-5-yl)-acetate Hydrochloride
26. Thieno(3,2-c)pyridine-5(4h)-acetic Acid, .alpha.-(2-chlorophenyl)-6,7-dihydro-, Methyl Ester, Hydrochloride, (s)-
Molecular Weight | 358.3 g/mol |
---|---|
Molecular Formula | C16H17Cl2NO2S |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 4 |
Exact Mass | 357.0357053 g/mol |
Monoisotopic Mass | 357.0357053 g/mol |
Topological Polar Surface Area | 57.8 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 381 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Secondary prevention of atherothrombotic events
Clopidogrel is indicated in:
- Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
- Adult patients suffering from acute coronary syndrome:
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
In patients with moderate to high-risk Transient Ischaemic Attack (TIA) or minor Ischaemic Stroke (IS)
Clopidogrel in combination with ASA is indicated in:
- Adult patients with moderate to high-risk TIA (ABCD2 score 4) or minor IS (NIHSS 3) within 24 hours of either the TIA or IS event.
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation
In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
For further information please refer to section 5. 1.
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:
- Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
For further information please refer to section 5. 1.
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:
- Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
- Patients suffering from acute coronary syndrome:
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
For further information please refer to section 5. 1.
Purinergic P2Y Receptor Antagonists
Compounds that bind to and block the stimulation of PURINERGIC P2Y RECEPTORS. Included under this heading are antagonists for specific P2Y receptor subtypes. (See all compounds classified as Purinergic P2Y Receptor Antagonists.)
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
B01AC04
B01AC06
B01AC04
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Clopidogrel Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Clopidogrel Hydrochloride, including repackagers and relabelers. The FDA regulates Clopidogrel Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Clopidogrel Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Clopidogrel Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Clopidogrel Hydrochloride supplier is an individual or a company that provides Clopidogrel Hydrochloride active pharmaceutical ingredient (API) or Clopidogrel Hydrochloride finished formulations upon request. The Clopidogrel Hydrochloride suppliers may include Clopidogrel Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Clopidogrel Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Clopidogrel Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Clopidogrel Hydrochloride Certificate of Suitability (COS). The purpose of a Clopidogrel Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Clopidogrel Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Clopidogrel Hydrochloride to their clients by showing that a Clopidogrel Hydrochloride CEP has been issued for it. The manufacturer submits a Clopidogrel Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Clopidogrel Hydrochloride CEP holder for the record. Additionally, the data presented in the Clopidogrel Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Clopidogrel Hydrochloride DMF.
A Clopidogrel Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Clopidogrel Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Clopidogrel Hydrochloride suppliers with CEP (COS) on PharmaCompass.
A Clopidogrel Hydrochloride written confirmation (Clopidogrel Hydrochloride WC) is an official document issued by a regulatory agency to a Clopidogrel Hydrochloride manufacturer, verifying that the manufacturing facility of a Clopidogrel Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Clopidogrel Hydrochloride APIs or Clopidogrel Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Clopidogrel Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Clopidogrel Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
Clopidogrel Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Clopidogrel Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Clopidogrel Hydrochloride GMP manufacturer or Clopidogrel Hydrochloride GMP API supplier for your needs.
A Clopidogrel Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Clopidogrel Hydrochloride's compliance with Clopidogrel Hydrochloride specifications and serves as a tool for batch-level quality control.
Clopidogrel Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Clopidogrel Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Clopidogrel Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Clopidogrel Hydrochloride EP), Clopidogrel Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Clopidogrel Hydrochloride USP).
LOOKING FOR A SUPPLIER?